Login / Signup

Current Perspectives on the Systemic Management of Atopic Dermatitis.

Danielle R DavariElizabeth L NiemanDiana B McShaneDean S Morrell
Published in: Journal of asthma and allergy (2021)
Atopic dermatitis (AD) is a common disease of childhood, and some patients experience a prolonged clinical course into adolescence and adulthood. Systemic management is required when AD is not adequately controlled with topical medications. Our aim is to provide a comprehensive review of commonly used systemic immunomodulating agents in childhood and adult AD, including cyclosporine A (CsA), azathioprine (AZA), methotrexate (MTX) and mycophenolate mofetil (MMF), which are prescribed off-label in the United States, as well as dupilumab, an FDA-approved biologic. We will also provide a brief overview of emerging systemic therapies currently under investigation.
Keyphrases
  • atopic dermatitis
  • depressive symptoms
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • high dose
  • prognostic factors
  • low dose
  • young adults
  • patient reported outcomes